Researchers develop nanodots to kill cancer cells selectively

Scientists at RMIT University have created tiny molybdenum oxide nanodots that destroy cancer cells by amplifying their internal stress, while leaving healthy cells largely intact. In lab tests, these particles proved three times more effective against cervical cancer cells than healthy ones. The early-stage research points to a potential for more precise cancer treatments.

A team led by Professor Jian Zhen Ou and Dr. Baoyue Zhang at RMIT University's School of Engineering has engineered ultrathin nanodots from molybdenum oxide, a metal compound typically used in electronics and alloys. By fine-tuning the particles' chemical structure with small additions of hydrogen and ammonium, the researchers enabled them to generate reactive oxygen species. These unstable molecules damage essential cell components, pushing cancer cells toward apoptosis, the body's programmed cell death mechanism.

Laboratory experiments demonstrated the nanodots' selectivity. Over 24 hours, they eliminated cervical cancer cells at three times the rate of healthy cells, without needing light activation—a departure from many similar technologies. In another test, the particles degraded a blue dye by 90 percent in just 20 minutes, even in darkness, highlighting their potent chemical reactivity.

"Cancer cells already live under higher stress than healthy ones," Zhang explained. "Our particles push that stress a little further—enough to trigger self-destruction in cancer cells, while healthy cells cope just fine."

The project drew on international expertise, including contributions from Dr. Shwathy Ramesan at The Florey Institute of Neuroscience and Mental Health in Melbourne, as well as researchers from Southeast University, Hong Kong Baptist University, and Xidian University in China. Funding came from the ARC Centre of Excellence in Optical Microcombs (COMBS).

While promising, the technology remains in preliminary lab testing with cell cultures only; no animal or human trials have occurred. Future efforts focus on tumor-specific delivery systems, controlled release of reactive oxygen, and collaborations for advanced testing and manufacturing. Using a common, non-toxic metal oxide, the nanodots could offer a cost-effective alternative to treatments relying on expensive noble metals like gold or silver, potentially reducing side effects from collateral damage to healthy tissues.

相关文章

ETH Zurich scientists with single-atom indium catalyst converting CO2 to methanol in a high-tech lab reactor, sustainable energy theme.
AI 生成的图像

Scientists develop single-atom catalyst for CO2-to-methanol conversion

由 AI 报道 AI 生成的图像

Researchers at ETH Zurich have engineered a catalyst using isolated indium atoms on hafnium oxide to convert CO2 and hydrogen into methanol more efficiently than previous methods. This single-atom design maximizes metal use and enables clearer study of reaction mechanisms. The breakthrough could support sustainable chemical production if powered by renewables.

Scientists at Oregon State University say they have engineered an iron-based nanomaterial that exploits acidic, peroxide-rich conditions inside tumors to generate two types of reactive oxygen species and kill cancer cells while largely sparing healthy cells. In mouse tests using human breast-cancer tumors, the team reports complete tumor regression without observable adverse effects, though the work remains preclinical.

由 AI 报道

Scientists have developed a light-based sensor that can identify tiny amounts of cancer biomarkers in blood samples, potentially enabling earlier detection than traditional scans. The technology combines DNA nanostructures, CRISPR, and quantum dots to produce a clear signal from just a few molecules. Tests on lung cancer patient serum showed promising results at sub-attomolar levels.

香港大学研究人员宣布开发出全球首款鼻喷剂,可将神经治疗粉末直接送达大脑,为缺血性中风患者提供急救。 该名为NanoPowder的药物旨在将脑损伤减少80%以上,并提高中风存活率。 临床试验预计于2030年前进行。

由 AI 报道

Researchers at Shandong University have modified the probiotic bacterium Escherichia coli Nissle 1917 to produce the anticancer drug Romidepsin directly in tumors. In mouse models of breast cancer, the engineered bacteria accumulated in tumors and released the drug. The findings were published on March 17 in PLOS Biology.

此网站使用 cookie

我们使用 cookie 进行分析以改进我们的网站。阅读我们的 隐私政策 以获取更多信息。
拒绝